Severe acute respiratory syndrome coronavirus

CEPI Boosts ‘Coronavirus X’ Vaccine Search With Expanded VBI Vaccines Deal

Retrieved on: 
Tuesday, December 6, 2022
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Nipah virus, Interim, Coalition for Epidemic Preparedness Innovations, Infection, Disease, Government of Canada, COVID-19, G7, Risk, Chikungunya, Cytomegalovirus, Virus, National Research Council, Partnership, Coronavirus, Epidemic, Multimedia, Vaccine, COVID-19 vaccine, Severe acute respiratory syndrome coronavirus 2, Glioblastoma, Middle East respiratory syndrome–related coronavirus, Omicron, Hepatitis B, Lassa mammarenavirus, Science, VLP, CEPI, CMV, Severe acute respiratory syndrome coronavirus, Immunity, Nature, COVAX, Immune system, NRC, Rift Valley fever, Pandemic, Research, Annual report, Human coronavirus 229E, Public sector, VBI, News, Safety, G20, GBM, Coalition, Animal, Pharmaceutical industry

The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) to advance the development of multivalent coronavirus shots that could be deployed against COVID-19 as well as a future Coronavirus X.

Key Points: 
  • The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) to advance the development of multivalent coronavirus shots that could be deployed against COVID-19 as well as a future Coronavirus X.
  • Application of this funding will now be directed into the broader development of the VBI-2900 coronavirus vaccine program to explore the Coronavirus X potential of VBIs technology.
  • We have long recognized the public health value that multivalent vaccines capable of anticipating new variants and coronavirus strains could provide.
  • VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.

Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022

Retrieved on: 
Monday, October 24, 2022
Physician, Union, Time, PH, Mycobacterium, Lung, Nitric oxide, Viral pneumonia, Disease, Risk, SEC, Urinary tract infection, Atmosphere of Earth, Virus, Pulmonary hypertension, Parasitism, Pulmonology, Community-acquired pneumonia, Severe acute respiratory syndrome coronavirus 2, Policy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NO2, Annual report, Patient, Fungus, Hospital, RSV, NO, Nontuberculous mycobacteria, Respiratory syncytial virus, NTM, Inflammation, Rhinovirus, Respiratory distress syndrome, Food, Company, Marketing, Hypoxemia, Kaplan–Meier estimator, Artery, Adult, Ageing, Bronchiolitis, Bacteria, Severe acute respiratory syndrome coronavirus, Forward-looking statement, Death, FDA, COVID-19, Pharmaceutical industry, Vaccine, H1N1

GARDEN CITY, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced positive data from the LungFit® PRO pilot study of high-concentration inhaled NO in Viral Community-Acquired Pneumonia (VCAP), including COVID-19.

Key Points: 
  • The Company has received FDA approval for its first system, LungFit PH for persistent pulmonary hypertension of the newborn.
  • Nitric Oxide is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions.
  • Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia.
  • In adults, viruses have been identified as the causative agents in approximately 100 million cases of community-acquired pneumonia per year.

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants

Retrieved on: 
Monday, September 12, 2022
Half-life, Probability, Safety, Gaps, Engineering, COVID-19, Virology, Severe acute respiratory syndrome coronavirus 2, Antibody, Intention, Company, Private Securities Litigation Reform Act, Immunity, Therapy, Forward-looking statement, U.S. Securities and Exchange Commission, High-functioning autism, CEO, Epitope, Technology, Annual report, Nasdaq, Degenerative disease, Severe acute respiratory syndrome coronavirus, Research, Infection, Security (finance), GLOBE, SEC, Disease, Vaccine, Omicron

The integrated Invivyd discovery platform generated dozens of potent and broadly neutralizing anti-SARS-CoV-2 monoclonal antibody candidates over the past two quarters.

Key Points: 
  • The integrated Invivyd discovery platform generated dozens of potent and broadly neutralizing anti-SARS-CoV-2 monoclonal antibody candidates over the past two quarters.
  • These molecules are all designed to be high-functioning and long-lasting with a high barrier to viral escape.
  • The companys antibody candidates are tuned to optimize across potency, breadth of neutralization, barrier to escape, and half-life.
  • Such antibodies may be deployed prior to exposure to SARS-CoV-2 to prevent disease or, once sick, to treat disease.

AIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-19 Treatment or Prevention

Retrieved on: 
Monday, June 13, 2022
Netherlands Patent Office, Human, Utah State University, EAP, Biomarker, PCT, Coronavirus, Outcome (probability), Company, COVID, Lists of diseases, Research, Antiviral drug, Infection, Survival, Fatigue, ORR, Patent, Invention, Severe acute respiratory syndrome coronavirus, Immunity, American, RNA, Cancer, Disease, Biological patent, AIM, Pancreatic cancer, Therapy, Cisplatin, Ovarian cancer, Pembrolizumab, Method, GLOBE, Patient, Mortality, Tumor microenvironment, Health, PLOS, NYSE, COVID-19, Immune system, Nivolumab, Food and Drug Administration, Severe acute respiratory syndrome coronavirus 2, Patent Cooperation Treaty, Degenerative disease, Interim, The Institute, Safety, Pharmaceutical industry, Vaccine, ME/CFS, Rintatolimod

2027383 a utility patent covering Ampligen (rintatolimod) and other AIM developed dsRNA products for use in the prevention or treatment of COVID-19, with a base patent term extending until 2041.

Key Points: 
  • 2027383 a utility patent covering Ampligen (rintatolimod) and other AIM developed dsRNA products for use in the prevention or treatment of COVID-19, with a base patent term extending until 2041.
  • Ampligen is AIMs RNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.
  • In another patent embodiment, the therapeutic double-stranded RNA product may be one or more of a number of therapeutic double-stranded RNA (tdsRNA) developed by AIM.
  • National patent application filings based on these PCTs, entitled to claim priority from the provisional patent applications, are ongoing.

Asian World Film Festival to Hold Taiwan Film Day in L.A.

Retrieved on: 
Friday, June 3, 2022
Life, FIPRESCI, Taiwanese Americans, 25th Tokyo International Film Festival, Landmark, Taipei Economic and Cultural Representative Office, Tokyo International Film Festival, SARS, Asian World Film Festival, Severe acute respiratory syndrome coronavirus, Greater Los Angeles, Culture, Golden Horse Film Festival and Awards, Cancer, Taipei Film Festival, Film, American

LOS ANGELES, June 3, 2022 /PRNewswire/ -- The Asian World Film Festival will be holding a special Taiwan Film Day this Sunday, June 5 at the Landmark in Westwood, together with the Taiwan Academy of the Taipei Economic Office and Cultural Office in Los Angeles and with the Asia Society Southern California. The event will feature a screening of American Girl at 4pm followed by a reception and Q&A with the film's Taiwanese director Fiona Feng-I Roan and producer Clifford Miu, winner and nominee at numerous major film festivals.

Key Points: 
  • LOS ANGELES, June 3, 2022 /PRNewswire/ -- The Asian World Film Festival will be holding a special Taiwan Film Day this Sunday, June 5 at the Landmark in Westwood, together with the Taiwan Academy of the Taipei Economic Office and Cultural Office in Los Angeles and with the Asia Society Southern California.
  • The event will feature a screening of American Girl at 4pm followed by a reception and Q&A with the film's Taiwanese director Fiona Feng-I Roan and producer Clifford Miu, winner and nominee at numerous major film festivals.
  • The main purpose of TAHW is to honor and recognize the contribution of Taiwanese Americans to the diversity and prosperity of American society.
  • Through the events of TAHW, we share and celebrate Taiwanese heritage with fellow Taiwanese Americans and the local community.

VBI Vaccines Announces New Data and Progress of VBI-2900, VBI’s eVLP Coronavirus Program

Retrieved on: 
Tuesday, April 5, 2022
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Private Securities Litigation Reform Act, Company, Virus, Glioblastoma, Coalition for Epidemic Preparedness Innovations, Epidemic, CEPI, Government of Canada, WHO, Partnership, Trial of the century, Severe acute respiratory syndrome coronavirus, Coronavirus, Cytomegalovirus, GBM, Mouse, Vaccine, RaTG13, CMV, Research, SEC, Government, VBI, NRC, CEO, Severe acute respiratory syndrome coronavirus 2, Immunity, Middle East respiratory syndrome–related coronavirus, Immune system, GMT, Omicron, Technology, Safety, Industry, CAD, RNA transfection, GM GMT platform, VLP, Nasdaq, COVID-19, Hepatitis B, National Research Council, Coalition, PB, Nature, FDA, Annual report, PNA, Disease, Infection, Pharmaceutical industry, Bridge, Animal, Lambda

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced updated clinical and preclinical data from its coronavirus program, VBI-2900.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced updated clinical and preclinical data from its coronavirus program, VBI-2900.
  • Moreover, we are excited by the preclinical data we have continued to generate with VBI-2901.
  • To stay one-step ahead of SARS-CoV-2 variants and other deadly coronaviruses, the world must invest in multivalent, broadly protective coronavirus vaccine technologieslike the eVLP technology being advanced by VBI.
  • VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Epidemiology Research Report, 2019-2021 & 2022-2032 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 7, 2022
Infectious Diseases, Pharmaceutical, Health, Table, Diagnosis, United Kingdom, SARS, Epidemiology, Coronavirus, Disease, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Classification, Animal, Pharmaceutical industry

This "Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Points: 
  • This "Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection epidemiology report gives a thorough understanding of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis.
  • The Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection epidemiology covered in the report provides historical as well as forecasted Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
  • The Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
    The Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Epidemiology Report and Model provide an overview of the global trends of Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
    The report provides insight into the historical and forecasted patient pool of Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan

SARS Coronavirus Infection Industry Report 2022-2032: Insights, Trends, and Future State of Worldwide Markets - ResearchAndMarkets.com

Retrieved on: 
Friday, February 25, 2022
Infectious Diseases, Pharmaceutical, Health, Comprehension, Therapy, Gaps, Awareness, Severe acute respiratory syndrome coronavirus, Epidemiology, Clinical trial, PESTLE, Disease, SWOT, Table, Acquisition, Growth–share matrix, Severe acute respiratory syndrome, Competition, News, SME, Technology, Porter's five forces analysis, Research, Lists of people executed in the United States, SARS, Animal, Pharmaceutical industry, Coronavirus, Phase II

This report delivers an in-depth understanding of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, historical and forecasted epidemiology as well as the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key Points: 
  • This report delivers an in-depth understanding of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, historical and forecasted epidemiology as well as the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection market report provides current treatment practices, emerging drugs, Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection market share of the individual therapies, current and forecasted Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection market size from 2019 to 2032 segmented by seven major markets.
  • The Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection epidemiology division provide insights about historical and current Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection patient pool and forecasted trend for every seven major countries.
  • Drug chapter segment of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection report encloses the detailed analysis of Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.

Virus-Like Particles (VLP's) Market Research Report 2021: Forecast to 2028 with COVID-19 Impact and Global Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 26, 2022
Infectious Diseases, Pharmaceutical, Health, COVID-19, Hepatitis, Food and Drug Administration, Coronavirus, Virus-like particle, PTM, Severe acute respiratory syndrome coronavirus, Therapy, Hepatitis C, HPV, HCV, Orthohantavirus, Government, RNA, Population, HBV, Cervarix, Chikungunya, VLP, FDA, Consistency, Virus, Hepatitis B, Growth, SARS, Incidence, Hepatitis B virus, Food, Hepatitis B Foundation, Mutation, Frontiers, A-DNA, Gaucher, Gaucher's disease, Safety, CAGR, DNA, Vaccine, Lassa mammarenavirus, Gardasil

The "Virus-like Particles (VLP's) Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Virus-like Particles (VLP's) Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.
  • However, the feasibility of VLPs as antigen carriers is questionable and complicated due to associated difficulties which is resulting in the sluggish growth of the global market.
  • The global virus-like particles (VLP's) market is segmented based on product type, source, and application.
  • Based on product type, the virus-like particles market is segmented as hepatitis, cancer/HPV, and Gaucher disease.

Roche receives CE mark for the use of saliva samples with cobas SARS-CoV-2 Qualitative test on cobas 6800/8800 Systems

Retrieved on: 
Friday, December 17, 2021
People, DJSI, Hoffmann-La Roche, Omicron, RNA, Genentech, Severe acute respiratory syndrome coronavirus 2, Death, Central nervous system, PCR, Essential medicines, COVID-19 testing, Veni, vidi, vici, Cough, European Centre for Disease Prevention and Control, Public health, Organic acid, World, COVID-19, Severe acute respiratory syndrome coronavirus, Family, Saliva, Risk, JAMA Network Open, Dow Jones, RO, Patient, System, Coinfection, Infection, Collection, Coronavirus, COV, Virus, Control, Genetically modified bacteria, Joint Medical Service (Germany), Ophthalmology, Severe acute respiratory syndrome, CHF, Human, ROG, Pharmaceutical industry, Vaccine, Medical device, Fine chemical, Chugai Pharmaceutical Co.

PLEASANTON, Calif., Dec. 17, 2021 /PRNewswire/ --Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its cobas SARS-CoV-2 Qualitative test has received CE mark for the use of saliva samples in the detection of SARS-CoV-2 on the widely available, high-throughput cobas 6800/8800 Systems.

Key Points: 
  • PLEASANTON, Calif., Dec. 17, 2021 /PRNewswire/ --Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its cobas SARS-CoV-2 Qualitative test has received CE mark for the use of saliva samples in the detection of SARS-CoV-2 on the widely available, high-throughput cobas 6800/8800 Systems.
  • Saliva sample collection represents a convenient testing approach for patients, who can easily self-collect their own samples.
  • "Expanding sensitive testing to include a non-invasive, easy-to-collect sample type such as saliva helps to improve access to screening for more people.
  • The test also provides patients with the option to self-collect their saliva sample on site, following the instructions of a healthcare professional.